Pharma BD Deal Intelligence

Eli Lilly and Company / Rigel Pharmaceuticals, Inc.

2021 · Licensing/Option · $960M · Terminated

Eli Lilly and Rigel entered a strategic collaboration to develop and commercialize RIPK1 inhibitors for inflammatory and autoimmune indications, plus CNS-penetrant RIPK1 candidates. Lilly paid $125M upfront and Rigel was eligible for up to $835M in development, regulatory and commercial milestones plus tiered royalties.

Key facts

• Announced Feb 18, 2021
• Deal value $960M
• Deal type Licensing/Option
• Therapeutic area Immunological and neurodegenerative diseases
• Indications Immunological and neurodegenerative diseases
• Key assets Ocadusertib (R552) and CNS-penetrant RIPK1 inhibitors
• Mechanism RIPK1 inhibitor

← Browse all deals  ·  How we score deals